Spyre Therapeutics Inc

Spyre Therapeutics’ CEO’s 10b5‑1 stock sales show disciplined insider trading, reinforcing long‑term commitment while hinting at short‑term volatility ahead of key UC/CD clinical milestones.

Spyre CEO Turtle Cameron sells 15,000 shares at premium—insider liquidity strategy amid investor‑conference buzz.

Spyre Therapeutics’ new executive option grants signal confidence and long‑term commitment to its IBD antibody pipeline, highlighting potential upside and investor interest.